Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
Authors:
- Quan ZhouQZQuan Zhou
- Xiao-Feng YanXYXiao-Feng Yan
- Wen-Sheng PanWPWen-Sheng Pan
- Su ZengSZSu Zeng
Open Access
- 1 January 2008
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (16) , 2617-2619
Abstract
Many of the drugs currently used in medical practice are racemates. The enantiomers of a racemic drug differ in pharmacodynamics and/or pharmacokinetics, thus in some cases it is preferable to develop pure enantiomers by racemic switch. In a recent study by Pai et al, dexrabeprazole [R(+)-rabeprazole] (10 mg) was found to be more effective than rabeprazole (20 mg) in the treatment of gastroesophageal reflux disease. We read with great interest in this study and discussed whether such racemic switch would be applicable to other proton-pump inhibitors (PPIs). A literature review indicates that stereoselective pharmacokinetics, rather than stereoselective pharmacological activity, is the main cause of differences in clinical efficacy between pure enantiomer and racemic PPI. Racemic switches of PPI provide the therapeutic advantages such as reducing metabolic load on the body, simplifying pharmacokinetics, providing benefit to the non-responders to standard dose of racemate, more homogenous response to treatment and better efficacy with equal safety. Further studies in quantitative structure-activity relationships (QSARs) are needed to address the fact that the preferred enantiomer of PPI is not always in the same absolute configuration, i.e., S-form is for omeprazole, pantoprazole and tenatoprazole whereas R-form is for lansoprazole and rabeprazole.Keywords
This publication has 11 references indexed in Scilit:
- Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux diseaseWorld Journal of Gastroenterology, 2007
- Enantioselective Disposition of Lansoprazole and Rabeprazole in Human PlasmaYAKUGAKU ZASSHI, 2006
- Comparative clinical trial of S-pantoprazoleversusracemic pantoprazole in the treatment of gastro-esophageal reflux diseaseWorld Journal of Gastroenterology, 2006
- The effect of rabeprazole and its isomers on aspirin and histamine-induced ulcers in ratsIndian Journal of Pharmacology, 2006
- Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigsJournal of Pharmacy and Pharmacology, 2005
- Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypesEuropean Journal of Clinical Pharmacology, 2004
- Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.2003
- Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical ConsequencesCurrent Drug Metabolism, 2002
- Effects of stereochemical aspects on drug interaction in pharmacokinetics.2002
- Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazoleAlimentary Pharmacology & Therapeutics, 2001